Abstract: Cancer is a large group of diseases involving disordered cell growth. In this type of disease (cancer), cells will grow and divide very fast
I. Introduction
Gastric cancer, or Stomach cancer, connect to cancer arising from any part of the stomach. Despite a main decrease in occurrence and mortality over several decades, Gastric cancer is still the fourth most common cancer and the second most common cause of cancer death in the world [1] . Stomach cancer can often be cured if it is recognized and treated at an early stage. Unfortunately, Prognosis of this cancer is poor (5-year survival <5 to 15%) because most patients introduce with advanced disease [2] .
Five types of standard treatment are used for treatment GC: Surgery, Chemotherapy, Radiation therapy, Chemo radiation, Targeted therapy. Today's more scientists are focused on Targeted therapy.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells [11] . Monoclonal antibody therapy and small molecules therapy are types of targeted therapy used in the treatment of gastric cancer [12] .
In monoclonal antibody therapy, these antibodies can identify substances or drugs on cancer cells or normal substances that may help cancer cells grow. The antibodies attach to the substances and kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. In small molecules therapy, using small molecules such as Gefitinib, Erlotinib to inhibit the tyrosine kinase activity, which is on the cytoplasmic side of the receptor.
The previous studies have shown, the epidermal growth factor receptor (EGFR) and one member of human epidermal growth factor (HER2), are observed in many kinds of human cancers, and have considered some small molecule drug candidates (such as Gefitinib, Erlotinib, Lapatinib, etc) to inhibit their protein targets activities [14, 16] . There is growing evidence that HER2 is an important biomarker and key driver of tumorigenesis in gastric cancer, with studies showing amplification or over expression in 7-34% of tumours [4] . The over expression of EGFR (Epidermal Growth Factor Receptor) occurs in 58-86% of gastric adenocarcinoma [4] .EGFR can be targeted from the outside of the cell by intravenous monoclonal antibodies against the target protein (also known as a ligand) binding portion of the cell, or from the inside of the cell by oral small molecule inhibitors against the part of the receptor called the tyrosine kinase domain that activates the intracellular machinery [4, 5] . Mutations affecting EGFR expression or activity could result in cancer. In addition EGFR drives the development of multiple solid tumor types, and EGFR provides a strong rationale for EGFR-TK as a targer molecule for the expansion of novel cancer therapies. HER1/EGFR dimers are capable of activating multiple downstream signaling pathways [7] .
Activation of HER1/EGFR mediated through ligand binding triggers a network of signaling processes that promote tumor cell proliferation, migration, adhesion, and angiogenesis, and decrease apoptosis. Therefore, inhibiting HER1/EGFR activity could effectively block downstream signaling events and, consequently, tumorigenesis [8] .
Amplification or over expression of HER2 has an important role in several types of cancer (The ERBB2 gene is also called HER2).
One method is using small molecules as inhibitors to inhibit the EGFR tyrosine kinase, which is on the cytoplasmic side of the receptor. Because without kinase activity, EGFR and HER2 cannot activate themselves, which are prerequisite for binding of downstream adaptor proteins. Finally the proliferation and migration of tumor is diminished by stopping the activity of cells that rely on this pathway [8, 16] . Gefitinib, Erlotinib, Trastuzumab and Lapatinib are examples of small molecule kinase inhibitors. It is noteworthy that we selected EGFR and HER2 as targets and considered -Gefitinim‖, -Erlotinib‖ and -lapatinib‖ as ligands.
Gefitinib (or Iressa) is a useful drug used for treatment of some type of cancers such as breast, lung and gastric cancer. Its chemical formula is C 22 H 24 ClFN 4 O 3 . Gefitinib is in the form of a tablet and it is used orally. Gefitinib is used to inhibit the activity of epidermal growth factor receptor (EGFR) in target cells [13] . The EGFR pathway is involved in regulating growth and replication of a cell. In many cancer cells, this pathway is abnormal and provides continual growth stimulation of a cell. Gefitinib blocks part of the epidermal growth factor receptor pathway so that the cellular growth signals are inhibited. [17] Actually Gefitinib is considered as the first selective inhibitor of epidermal growth factor receptor's tyrosine kinase domain. It inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK).
Gefitinib in the first step binds to the adenosine triphosphate (ATP)-binding site of the enzyme, after that inhibits EGFR tyrosine kinase. Thus the function of the EGFR tyrosine kinase is inhibited, and malignant cells are inhibited. Erlotinib hydrochloride (Tarceva or OSI-774) is used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Its chemical formula is C 22 H 23 N 3 O 4 . Erlotinib belongs to the quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. We can use Erlotinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unrespectable or metastatic pancreatic cancer [18] .
The target of Erlotinib (Similar to Gefitinib) is the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor.
II. Softwares And Databases And Methodes
In the present study we have used Blind Docking method to predict the binding orientation of small molecule drug candidates (Gefitinib-Erlotinib-Lapatinib) to their protein targets (HER2-EGFR) in order to predict the affinity and activity of the small molecule when bound to each other to form a stable complex. For this aim we used some software and database such as, AutoDock Vina, Protein Data Bank, Pub Chem, Drug Bank and Discovery Studio visualize.
Receptor preparation:
In the first step we download the 3D crystal structures of HER1 and HER2 as target or receptor in pdb format from Protein Data Bank. (PDB ID of HER1 is 3W2S and PDB ID of HER2 is 3PP0)
The structure of HER2
The structure of HER1
Ligand preparation:
In second step, download the structure of Gefitinib from PubChem compound, with CID-123631, and 14 other compound structures with 98% structure similarity from PubChem Structure Search, also for Lapatinib with CID-208908, and 14 other compound structures with 97% structure similarity and for Erlotinib with CID-176870, and 14 other compound structures with 95% structure similarity.
Make Grid box and Configuration file:
In Vina we must be determine a grid center and grid dimensions for AutoDock calculation. The grids increments of 1.00 Angstrom because to adjust the spacing to same range. By input the center of the grid we can determine adjust the grid size. The grid dimensions can change between 1 to 40 Angstroms. Make the configuration file to prepare to run vina tool. In config file we can save the information, such as the grid box and the center of mass of target protein. Table1: Configuration files of HER1 and HER2
Run AutoDock:
To run AutoDock Vina, we have to go to the command prompt. In command prompt we write the address of our file . 
Output of Docking:
We have done docking for each of the selected ligands to HER1 and HER2 (as targets). 
III. Conclusion
Based on the value of bonding energy, the best compound with high stability has minimum value of energy. In conclusion and according of our analysis, we can consider that: 1.
For HER1 receptor and Erlotinib similarity compounds, the first ligand that we can choose is the substance with CID-25125154, because it has minimum energy between these 15 compounds and it also has maximum H-bond ( 4 H-bonds) as the best. The second best ligand is the substance with CID-25125156, because it has lowest energy. For HER2 receptor and Erlotinib similarity compounds, the first ligand that we can select is the substance with CID-25125156, because it has lowest energy between these 15 compounds and it also has maximum H-bond (3 H-bonds) as the best. The second best ligand is the substance with CID-25125159, because it also has minimum value of energy and 2 H-bonds. For HER1 receptor and Gefitinib similarity compounds, the first ligand that we can choose is the substance with CID-11604752, because it has minimum energy between these 15 compounds and it also has maximum H-bond ( 6 H-bonds) as the best. The second best ligand is the substance with CID-44158624, because it also has lowest energy and 3 H-bonds. For HER2 receptor and Gefitinib similarity compounds, the first ligand that we can select is the substance with CID-44158624, because it has lowest energy between these 15 compounds as the best. Another best ligands are the substances with CID-44158626 and CID-46243752 , because they also have minimum value of energy. 
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5.
For HER1 receptor and Lapatinib similarity compounds, the first ligand that we can choose is the substance with CID-44199992, because it has minimum energy and maximum numbers of H-bonds (5 Hbonds) between these 13 compounds, as the best.The second best ligand is the substance with CID-10438224, because it also has lowest energy and 5 H-bonds. For HER2 receptor and Lapatinib similarity compounds, the first ligand that we can select is the substance with CID-44199993, as the best because it has lowest energy and highest number of H-bonds (6 Hbonds) between these 13 compounds . Another best ligand is the substances with CID-10438224, because it also has minimum value of energy and 5 H-bonds. 
